GCM
AUPH icon

Graham Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Graham Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,432
Closed -$230K – 1163
2025
Q4 		$230K Buy
+14,432
New +$205K 0.01% 977
2025
Q3 		– Sell
-17,323
Closed -$147K – 1244
2025
Q2 		$147K Sell
17,323
-20,310
-54% -$163K ﹤0.01% 1170
2025
Q1 		$303K Buy
37,633
+26,224
+230% +$212K 0.01% 994
2024
Q4 		$102K Buy
+11,409
New +$93.1K ﹤0.01% 1155
2023
Q4 		– Sell
-68,448
Closed -$532K – 999
2023
Q3 		$532K Buy
+68,448
New +$669K 0.01% 544

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Graham Capital Management's AUPH Position: Q1 2026 in Review

Graham Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2026, closing a stake of 14,432 shares — an estimated $230K sold.

Graham Capital Management first reported a position in AUPH in Q3 2023 and held it in 5 quarters. The position peaked at $532K in Q3 2023. 260 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Graham Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 14,432 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $230K.
  • Graham Capital Management first reported a position in Aurinia Pharmaceuticals in Q3 2023 and held it in 5 quarters.
  • Graham Capital Management's Aurinia Pharmaceuticals position peaked at $532K in Q3 2023.
  • 260 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.